BRPI0716742A2 - Lactamas terapêuticas - Google Patents

Lactamas terapêuticas

Info

Publication number
BRPI0716742A2
BRPI0716742A2 BRPI0716742A BRPI0716742A2 BR PI0716742 A2 BRPI0716742 A2 BR PI0716742A2 BR PI0716742 A BRPI0716742 A BR PI0716742A BR PI0716742 A2 BRPI0716742 A2 BR PI0716742A2
Authority
BR
Brazil
Prior art keywords
lactams
therapeutic
therapeutic lactams
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
David W Old
Robert M Burk
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0716742A2 publication Critical patent/BRPI0716742A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0716742 2006-08-11 2007-08-09 Lactamas terapêuticas BRPI0716742A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82210806P 2006-08-11 2006-08-11
PCT/US2007/075615 WO2008021975A2 (en) 2006-08-11 2007-08-09 Therapeutic lactams

Publications (1)

Publication Number Publication Date
BRPI0716742A2 true BRPI0716742A2 (pt) 2015-03-24

Family

ID=38683367

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0716742 BRPI0716742A2 (pt) 2006-08-11 2007-08-09 Lactamas terapêuticas

Country Status (11)

Country Link
US (2) US7482475B2 (enExample)
EP (1) EP2066660A2 (enExample)
JP (1) JP2010500416A (enExample)
KR (1) KR101422305B1 (enExample)
CN (1) CN101522669B (enExample)
AU (1) AU2007286177B2 (enExample)
BR (1) BRPI0716742A2 (enExample)
CA (1) CA2660608A1 (enExample)
MX (1) MX2009001578A (enExample)
NZ (1) NZ597866A (enExample)
WO (1) WO2008021975A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2007226957B2 (en) * 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
EP2066660A2 (en) * 2006-08-11 2009-06-10 Allergan, Inc. Therapeutic lactams
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams
US7820661B2 (en) * 2008-04-24 2010-10-26 Allergan, Inc. Substituted gamma lactams as therapeutics agents
WO2014031581A1 (en) * 2012-08-21 2014-02-27 Allergan, Inc. Process for the synthesis of substituted gamma lactams
US20150274658A1 (en) * 2014-03-27 2015-10-01 Allergan, Inc. Therapeutic lactams
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1991504A (en) * 1928-09-12 1935-02-19 American District Telegraph Co Key-trapping valve lock for transmitter-supervised sprinkler systems
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
JP2006504679A (ja) * 2002-08-28 2006-02-09 メルク フロスト カナダ アンド カンパニー 緑内障の治療においてep4受容体作動薬として使用するためのオキサゾリジン−2−オンおよびチアゾリジン−2−オン誘導体
WO2006061366A1 (en) * 2004-12-06 2006-06-15 Laboratoires Serono S.A. Pyrrolidin-2-one derivatives for use as dp1 receptor agonists
EP1856042B1 (en) * 2005-03-10 2012-06-27 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2007226957B2 (en) * 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
EP2066660A2 (en) * 2006-08-11 2009-06-10 Allergan, Inc. Therapeutic lactams

Also Published As

Publication number Publication date
US20080039505A1 (en) 2008-02-14
AU2007286177A1 (en) 2008-02-21
US20090099249A1 (en) 2009-04-16
KR20090038937A (ko) 2009-04-21
CA2660608A1 (en) 2008-02-21
CN101522669B (zh) 2013-01-16
AU2007286177B2 (en) 2012-06-14
WO2008021975A3 (en) 2008-07-10
KR101422305B1 (ko) 2014-07-22
EP2066660A2 (en) 2009-06-10
MX2009001578A (es) 2009-02-19
US7482475B2 (en) 2009-01-27
CN101522669A (zh) 2009-09-02
US8686025B2 (en) 2014-04-01
WO2008021975A2 (en) 2008-02-21
NZ597866A (en) 2013-08-30
JP2010500416A (ja) 2010-01-07

Similar Documents

Publication Publication Date Title
NO2025041I1 (no) Lecanemab
NL301235I2 (nl) abaloparatide
CY2018004I1 (el) Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης
DK2035369T3 (da) Terapeutiske
ES1063346Y (es) Andador
CR10841A (es) Imidazotriazinas imidazopirimidinas inhibidores de cinasa
DK2081937T3 (da) Triazolopyridazin-proteinkinasemodulatorer
DE602007013937D1 (de) Torantagonisten
AT504580A3 (de) Scan-einrichtung
DK2144905T3 (da) Terapeutiske midler
DE502007001629D1 (de) Rfahren
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE502007000361D1 (de) Stanznieteinheit
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
DE112007003147A5 (de) Rohr-Biegevorrichtung
DE502007001652D1 (de) Notöltank
DE502007005975D1 (de) Wischblatt
DE502007006319D1 (de) Staubabsaugadaptervorrichtung
BRPI0719956A2 (pt) Radiofluoração
DE102006045567A8 (de) Crimpstabilisierung
DE112007001125A5 (de) Käfigmutter
PT2444812E (pt) Métodos de imunoensaio melhorados

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.